K
Kulbhaskar
About Kulbhaskar
Data last updated:
Kulbhaskar has 11 years in corporate governance. Holds Director role. Currently with 2 companies, including Syndrome Pharmaceuticals Private Limited and Didhirsha Private Limited. Engaged in General Business. Contributes to corporate operations. The largest current company by reported revenue is Syndrome Pharmaceuticals Private Limited at ₹1.17 Cr (FY 2025).
Current companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
 Syndrome Pharmaceuticals Private Limited U24230BR2009PTC014515 | Director | 20 Oct 2014 | 2009 | ₹1.17 Cr (FY 2025) | Active |
| Didhirsha Private Limited U74999BR2018PTC039635 | Director | 04 Nov 2024 | 2018 | – | Active |
Previous companies
Explore Director's current and past company associations Uncover their professional journey today!
Directorship timeline
Open interactive timeline →Shareholding and investment profile for Kulbhaskar
Company-level share counts, filed values, and quarterly changes require authenticated premium access.
- Company-level holdings
- Filed share counts
- Reported values
- Quarterly changes
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Kulbhaskar
Kulbhaskar has 11 years in corporate governance. Holds Director role. Currently with 2 companies, including Syndrome Pharmaceuticals Private Limited and Didhirsha Private Limited. Engaged in General Business. Contributes to corporate operations. The largest current company by reported revenue is Syndrome Pharmaceuticals Private Limited at ₹1.17 Cr (FY 2025).
Kulbhaskar is associated with 2 companies as Director, including Syndrome Pharmaceuticals Private Limited (₹1.17 Cr), Didhirsha Private Limited.
Kulbhaskar has expertise in General Business.
Kulbhaskar has 11 years in corporate governance.
By reported revenue, the largest current company of Kulbhaskar is Syndrome Pharmaceuticals Private Limited, with revenue of ₹1.17 Cr (FY 2025).
Kulbhaskar currently holds positions at 2 companies: Syndrome Pharmaceuticals Private Limited (₹1.17 Cr), Didhirsha Private Limited.